13.065 USD
-0.26 (-1.91%)
Taking everything into account, NVCR scores 2 out of 10 in our fundamental rating. NVCR was compared to 187 industry peers in the Health Care Equipment & Supplies industry. NVCR has a bad profitability rating. Also its financial health evaluation is rather negative. NVCR is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
NVCR had negative earnings in the past year.
NVCR had a negative operating cash flow in the past year.
NVCR had negative earnings in 4 of the past 5 years.
In multiple years NVCR reported negative operating cash flow during the last 5 years.
1.2 Ratios
NVCR has a Return On Assets (-13.05%) which is in line with its industry peers.
With a Return On Equity value of -52.05%, NVCR perfoms like the industry average, outperforming 51.87% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.05% | ||
| ROE | -52.05% | ||
| ROIC | N/A |
ROA(3y)-13.14%
ROA(5y)-8.53%
ROE(3y)-41.63%
ROE(5y)-26.99%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 75.57%, NVCR belongs to the top of the industry, outperforming 86.63% of the companies in the same industry.
In the last couple of years the Gross Margin of NVCR has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for NVCR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 75.57% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
NVCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NVCR has been increased compared to 1 year ago.
Compared to 5 years ago, NVCR has more shares outstanding
NVCR has a worse debt/assets ratio than last year.
2.2 Solvency
NVCR has an Altman-Z score of 0.00. This is a bad value and indicates that NVCR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.00, NVCR is in line with its industry, outperforming 44.38% of the companies in the same industry.
NVCR has a Debt/Equity ratio of 2.21. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of NVCR (2.21) is worse than 81.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.21 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0 |
ROIC/WACCN/A
WACC6.55%
2.3 Liquidity
NVCR has a Current Ratio of 1.55. This is a normal value and indicates that NVCR is financially healthy and should not expect problems in meeting its short term obligations.
NVCR has a worse Current ratio (1.55) than 73.26% of its industry peers.
A Quick Ratio of 1.50 indicates that NVCR should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.50, NVCR is in line with its industry, outperforming 41.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.55 | ||
| Quick Ratio | 1.5 |
3. Growth
3.1 Past
NVCR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.00%.
Looking at the last year, NVCR shows a quite strong growth in Revenue. The Revenue has grown by 11.17% in the last year.
Measured over the past years, NVCR shows a quite strong growth in Revenue. The Revenue has been growing by 11.49% on average per year.
EPS 1Y (TTM)-15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.86%
Revenue 1Y (TTM)11.17%
Revenue growth 3Y4.2%
Revenue growth 5Y11.49%
Sales Q2Q%7.81%
3.2 Future
Based on estimates for the next years, NVCR will show a very strong growth in Earnings Per Share. The EPS will grow by 23.02% on average per year.
The Revenue is expected to grow by 19.52% on average over the next years. This is quite good.
EPS Next Y9.53%
EPS Next 2Y1.15%
EPS Next 3Y8.91%
EPS Next 5Y23.02%
Revenue Next Year8.7%
Revenue Next 2Y7.15%
Revenue Next 3Y9.29%
Revenue Next 5Y19.52%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
NVCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NVCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.15%
EPS Next 3Y8.91%
5. Dividend
5.1 Amount
No dividends for NVCR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:NVCR (12/15/2025, 3:22:46 PM)
13.065
-0.26 (-1.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners83.34%
Inst Owner Change-2.9%
Ins Owners2.76%
Ins Owner Change0.3%
Market Cap1.46B
Revenue(TTM)642.27M
Net Income(TTM)-177.65M
Analysts81.54
Price Target25.43 (94.64%)
Short Float %5.93%
Short Ratio3.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.64%
Min EPS beat(2)8.12%
Max EPS beat(2)23.15%
EPS beat(4)3
Avg EPS beat(4)-2.03%
Min EPS beat(4)-73.92%
Max EPS beat(4)34.54%
EPS beat(8)7
Avg EPS beat(8)8.46%
EPS beat(12)8
Avg EPS beat(12)0.73%
EPS beat(16)10
Avg EPS beat(16)-6.5%
Revenue beat(2)2
Avg Revenue beat(2)1.97%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.98%
Revenue beat(4)4
Avg Revenue beat(4)1.94%
Min Revenue beat(4)0.18%
Max Revenue beat(4)3.65%
Revenue beat(8)7
Avg Revenue beat(8)3.15%
Revenue beat(12)7
Avg Revenue beat(12)1.16%
Revenue beat(16)9
Avg Revenue beat(16)0.67%
PT rev (1m)-7.46%
PT rev (3m)-9.35%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20.19%
EPS NY rev (1m)1.39%
EPS NY rev (3m)12.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.52%
Revenue NY rev (1m)0.2%
Revenue NY rev (3m)2.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.28 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.29 | ||
| P/tB | 4.29 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.61
EYN/A
EPS(NY)-1.52
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS5.74
BVpS3.05
TBVpS3.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.05% | ||
| ROE | -52.05% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 75.57% | ||
| FCFM | N/A |
ROA(3y)-13.14%
ROA(5y)-8.53%
ROE(3y)-41.63%
ROE(5y)-26.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5Y0.68%
F-Score2
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.21 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 226.76% | ||
| Cap/Sales | 4.78% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.55 | ||
| Quick Ratio | 1.5 | ||
| Altman-Z | 0 |
F-Score2
WACC6.55%
ROIC/WACCN/A
Cap/Depr(3y)276.52%
Cap/Depr(5y)245.8%
Cap/Sales(3y)5.46%
Cap/Sales(5y)4.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.86%
EPS Next Y9.53%
EPS Next 2Y1.15%
EPS Next 3Y8.91%
EPS Next 5Y23.02%
Revenue 1Y (TTM)11.17%
Revenue growth 3Y4.2%
Revenue growth 5Y11.49%
Sales Q2Q%7.81%
Revenue Next Year8.7%
Revenue Next 2Y7.15%
Revenue Next 3Y9.29%
Revenue Next 5Y19.52%
EBIT growth 1Y-10.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.16%
EBIT Next 3Y27.38%
EBIT Next 5Y42.57%
FCF growth 1Y26.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.83%
OCF growth 3YN/A
OCF growth 5YN/A
NOVOCURE LTD / NVCR FAQ
What is the fundamental rating for NVCR stock?
ChartMill assigns a fundamental rating of 2 / 10 to NVCR.
What is the valuation status for NVCR stock?
ChartMill assigns a valuation rating of 0 / 10 to NOVOCURE LTD (NVCR). This can be considered as Overvalued.
Can you provide the profitability details for NOVOCURE LTD?
NOVOCURE LTD (NVCR) has a profitability rating of 2 / 10.